N,N'-Methylenebisacrylamide Cas: 110-26-9 98% Pauda keʻokeʻo
| Helu Helu | XD90231 |
| inoa mea kūʻai | N,N'-Methylenebisacrylamide |
| CAS | 110-26-9 |
| ʻĀpana Molekala | C7H10N2O2 |
| Kaumaha Molecular | 154.1665 |
| Nā kikoʻī mālama | 2 a 8 °C |
| Kānāwai Kūʻai Kūlike | 29241900 |
Huahana Huahana
| Hoʻāʻo | >98% |
| ʻAʻole hiki ke hoʻonā wai | <0.5% |
| Ka nana aku | Pauda keʻokeʻo |
| ʻO nā sulfate anorganic | <0.5% |
| No ka noiʻi wale nō, ʻaʻole no ke kanaka | noiʻi wale nō, ʻaʻole no ke kanaka |
ʻO ka hana koʻikoʻi o nā fibroblasts pili i ka tumo (TAF) i ka holomua ʻana o ka maʻi maʻi i kēia manawa ua akaka i ka maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi (NSCLC).Eia nō naʻe, ua kaupalena ʻia nā lāʻau lapaʻau e kūʻē i nā TAF ma muli o ka ʻike ʻole i nā ʻano hana subtype-specific i lalo o kā lākou hōʻiliʻili ʻana.Ma ʻaneʻi, ua ʻoki ʻia ka mīkini (ʻo ia hoʻi, ʻo ka matrix rigidity) a me ka soluble mitogenic cues e alakaʻi i ka hōʻiliʻili ʻana o nā TAF mai nā subtypes NSCLC nui: adenocarcinoma (ADC) a me squamous cell carcinoma (SCC).Hoʻoulu ʻia nā fibroblasts ma luna o ka substrata i hana ʻia e hōʻike i ka ʻoʻoleʻa maʻamau a i ʻole ke ʻano o ka tumo i nā ʻano serum like ʻole, a ua wehewehe ʻia nā kaʻina hoʻoponopono koʻikoʻi.I ka hoʻomalu ʻana i nā fibroblasts mai ka ʻiʻo nonmalignant, ʻo ka ʻoʻoleʻa matrix wale nō i hoʻonui i ka hōʻiliʻili ʻana o ka fibroblast, a ʻo kēia hopena mechanical i mana a hoʻohālikelike ʻia me nā mea ulu hiki ke hiki i ka 0.5% serum.Ua alakaʻi ʻia nā hōʻailona hoʻoikaika o ka matrix rigidity e ka β1 integrin mechano-sensing ma o FAK (pY397), a ua pili pū me ka piʻi ʻana o ka posttranscriptionally i ka β1 integrin expression.Ua ʻike pū ʻia ke kaʻapuni mechano-regulatory hope ma TAF akā ma kahi ʻano subtype-specific, no ka mea, ua hōʻike ʻo SCC-TAF i ka FAK kiʻekiʻe (pY397), ʻōlelo β1, a me ERK1/2 (pT202/Y204) ma mua o ADC-TAF.Eia kekahi, ʻo ka paʻakikī matrix i hoʻoulu i ka hōʻiliʻili TAF nui ma SCC-TAFs (> 50%) i hoʻohālikelike ʻia me ADC-TAFs (10% -20%).I ka hoʻohālikelike ʻana, ua hoʻokaʻawale ʻia nā SCC-TAF i ka nui o ka serum desensitized, aʻo ADC-TAFs i pane i ke kiʻekiʻe serum concentration wale nō.Hāʻawi kēia mau ʻike i ka hōʻike mua o ka hoʻoponopono subtype-specific o ka hōʻiliʻili NSCLC-TAF.Eia kekahi, kākoʻo kēia mau ʻikepili i nā lāʻau lapaʻau e manaʻo ana e hoʻihoʻi i ka elasticity māmā maʻamau a me / a i ʻole β1 integrin-dependent mechano regulation i hiki ke kūpono i ka SCC-TAFs, akā ʻo ka pale ʻana i ka hōʻailona stromal growth factor hiki ke kūpono i ka ADC-TAFs. ka hōʻiliʻili ʻino ʻana o nā fibroblasts kākoʻo tumo i loko o ʻelua mau ʻano nui o ka maʻi ʻaʻai māmā, kahi e kōkua ai i ka hoʻomohala ʻana i nā lāʻau lapaʻau pilikino e kūʻē i kēia mau cell.
